

1636  
#



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

TELEPHONE: 512/474-4300  
FACSIMILE: 512/536-4339  
STEVEN L. HIGHLANDER  
PARTNER  
INTERNET ADDRESS:  
SHIGHLANDER@FULBRIGHT.COM  
DIRECT DIAL: 512/536-3184

RECEIVED


MAR 12 2002

February 21, 2002

TECH CENTER 1600/2900

FILE: IOWA:042USD1  
10107932

COPY OF PAPERS  
ORIGINALLY FILED

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
February 21, 2002 Date	 Steven L. Highlander

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/612/809 "THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART DISEASE BASED ON A NOVEL HUMAN TRANSCRIPTION FACTOR" - By Val C. Sheffield

Commissioner:

Enclosed for filing in the above-referenced patent application is:


1. Amendment and Request for Reconsideration Under 37 C.F.R. §1.111;
2. A Request for an Extension of Time of three months to and including February 21, 2002;
3. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
4. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated June 29, 2001;
5. Statement as Required Under 37 C.F.R. § 1.821(f); Paper Copy of Sequence Listing; Computer Readable Form (CRF); and
6. A check for \$920.00 as the fee for the extension of time; and

Commissioner for Patents  
February 21, 2002  
Page 2

7. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107932/SLH.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642

SLH/cpj  
Encl.:

RECEIVED

MAR 12 2002

TECH CENTER 1600/2900



CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
February 21, 2002 Date	Steven L. Highlander

COPY OF PAPERS  
ORIGINALLY FILED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Val C. SHEFFIELD et al.

Serial No.: 09/612,809

Filed: July 10, 2000

For: THERAPEUTICS AND DIAGNOSTICS  
FOR CONGENITAL HEART DISEASE  
BASED ON A NOVEL HUMAN  
TRANSCRIPTION FACTOR

Group Art Unit: 1636

Examiner: SCHARWTZMAN, R.

Atty. Dkt. No.: IOWA:042USD1/SLH

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES DATED AUGUST 21, 2001**

Commissioner for Patents  
Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 21, 2001 for which the three-month date for response was November 21, 2001.

A request for a three-month extension of time to respond is included herewith along with the required fee. This three-month extension will bring the due date to February 21, 2002, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under


37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107932/SLH.

**RESPONSE TO NOTICE**

Submitted herewith is a Statement As Required Under 37 C.F.R. § 1.821(f); paper copy of sequence listing and computer readable form (CRF) which comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Applicants believe that the attached documents fully respond to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures for this application.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: February 21, 2002